Treatment of abdominal pain in IBS remains a highly unmet medical need. Lyntonix has discovered a novel mechanism underlying pain hypersensitivity in IBS. Serotonin receptor type 7 (5-HT7R ) found in the intestinal tissues of IBS patients was identified as a new therapeutic target and the team has developed DC105 through rigorous drug design and optimization. LTX-568 demonstrates high target specificity, effectively reduces visceral hypersensitivity via oral administration, and exhibits an excellent safety profile.

Recent profound breakthroughs and progress:

• The IBS animal model developed by Lyntonix and the analgesic efficacy of LTX-568 have been validated through third-party verification conducted by the Development Center for Biotechnology (DCB), demonstrating the reproducibility of both the new IBS animal model and the pain-relieving effect of LTX-568 in IBS mice.
• The preformulation study has been completed, showing that a single oral dose provides up to 24 hours of efficacy.
• Repeated-dose toxicity studies in rats and dogs have been completed, confirming a high level of safety.
• Patent coverage for major global IBS drug markets has been secured.